Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Drug Regulators Issue Warning On Use Of Avandia While Debating Suspension Vs. Restricted Use

This article was originally published in The Pink Sheet Daily

Executive Summary

China's oral diabetes market is projected to reach $380 million by year's end.
Advertisement

Related Content

As More Leading Doctors Oppose Avandia, Will Indian Regulators Propose A Ban?
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia
Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia

Topics

Advertisement
UsernamePublicRestriction

Register

PS071245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel